A One-Time Cell Therapy to Reset the Immune System in Autoimmune Diseases

People with rare, severe autoimmune diseases often live for years with progressive, disabling conditions managed by chronic immunosuppression that rarely addresses the underlying cause. Kyverna is developing an autologous CAR T-cell therapy designed to deliver a deep immune reset by broadly depleting pathogenic B cells, followed by repopulation with naïve, non-pathogenic B cells and normalization of T-cell function and cytokine profiles. This approach has the potential to enable durable remissions and discontinuation of background immunosuppressive therapies after a single infusion. The company’s pipeline is focused on neuroimmunology, with lead programs in generalized myasthenia gravis and stiff person syndrome. Warner Biddle, CEO of Kyverna Therapeutics, discusses the company’s B cell–targeting cell therapy platform, the range of autoimmune diseases it aims to address, and its next-generation therapies in development.